Allergy Therapeutics plc (LON:AGY – Get Free Report) dropped 6.7% during mid-day trading on Monday. The stock traded as low as GBX 3.43 and last traded at GBX 3.50. Approximately 210,300 shares were traded during trading, a decline of 37% from the average daily volume of 332,814 shares. The stock had previously closed at GBX 3.75.
Allergy Therapeutics Trading Down 6.7%
The company has a market cap of £221.64 million, a PE ratio of -3.61, a price-to-earnings-growth ratio of -30.70 and a beta of 0.83. The company has a debt-to-equity ratio of 629.58, a current ratio of 1.13 and a quick ratio of 1.48. The company has a 50-day moving average of GBX 4.90 and a 200 day moving average of GBX 8.10.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Featured Articles
- Five stocks we like better than Allergy Therapeutics
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
